Search results
Showing 1231 to 1245 of 2005 results for nice guidelines
Home What NICE does Digital health...
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
of focal and generalised seizures since publication of the original NICE guideline on epilepsy in 2004 have not been...
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
How to register with us as a diagnostic technologies stakeholder.
How to register with us as a diagnostic technologies stakeholder.
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)
NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns